ANRO vs APLM

Alto Neuroscience, Inc. vs Apollomics Inc. — Valuation Comparison 2026

ANRO

Biotechnology
Alto Neuroscience, Inc.
Quality
4.7
out of 10
Value Trap
12
SAFE
Price
$20.22
Last close
Models
7/13
Active
VS

APLM

Biotechnology
Apollomics Inc.
Quality
1.8
out of 10
Value Trap
Price
$14.06
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType ANRO Fair ValueANRO Upside APLM Fair ValueAPLM Upside
Bayesian DCF Intrinsic $7.06 -65.1% $3.72 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.90 -90.6% $0.68 -95.5%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $15.79 -21.9% $12.28 -11.9%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ANRO vs APLM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ANRO vs APLM — Which Stock Is More Undervalued?

ANRO scores higher with a 4.7/10 quality rating vs APLM's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Alto Neuroscience, Inc. (ANRO) and Apollomics Inc. (APLM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ANRO currently trades at $20.22 with a QOC of 4.7/10, while APLM trades at $14.06 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).